1. Medical Properties Trust (MPT) is currently undervalued due to recent fundamental contractions; 2. The company is selling assets to improve liquidity, impacting long-term income and capital gains opportunities; 3. Despite potential near-term upside, long-term investors are primarily paying for the dividend yield, with a Hold rating recommended.

1. Palantir's intrinsic value continues to increase, supported by robust core business growth. 2. The company demonstrates strong sales efficiency and is rewarded in the market for it. 3. Despite being the most expensive SaaS company, Palantir is not overvalued and is fairly priced based on its intrinsic value.

1. PLD is expected to benefit from market condition improvements in 2025. 2. Management has revised its 2024 guidance for core FFO per share and acquisition volume upwards. 3. PLD maintains solid business metrics and a strong balance sheet with top-tier credit metrics in the industry.

1. Digital Turbine's revenue, margins, and interest payments continue to decline. 2. The company's stock appears cheap, but historical estimates have been overly optimistic. 3. Management offers no clear plans for a turnaround, suggesting continued caution.